BioSpace News Archive

Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that the U.S. Food and Drug Administration (“FDA”) approved a single-dose, prefilled autoinjector presentation of UDENYCA® (pegfilgrastim-cbqv), a biosimilar pegfilgrastim administered the day after chemotherapy to decrease the incidence of infection as manifested by febrile neutropenia.

Bio-Thera Solutions, Ltd., a commercial-stage pharmaceutical company, announced that dosing has begun in a Phase 1 clinical study evaluating BAT8010, an antibody-drug conjugate that targets HER2.

Positive topline results from an analysis of the ongoing DESTINY-PanTumor02 phase 2 trial showed treatment with Daiichi Sankyo and AstraZeneca’s ENHERTU® met the pre-specified target for objective response rate and demonstrated durable response across multiple HER2 expressing advanced solid tumors in heavily pre-treated patients.

Shoulder Innovations Inc., a Grand Rapids, Michigan based leader in the shoulder replacement implant market, announced closing on an oversubscribed $42 million Series D financing.

RadNet, Inc. announced that Mark Stolper, Executive Vice President and Chief Financial Officer and Gregory Sorensen, M.D., CEO and co-founder of DeepHealth, will be presenting at the Cowen & Company Healthcare Conference on Tuesday, March 7, 2023 at 9:50 a.m. Eastern Time.

The Access to Advanced Health Institute published results of a Phase 1 clinical trial demonstrating the safety and immune responses in a new vaccine against tuberculosis, the world’s second deadliest infectious disease.

Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr. Megan Baldwin, the Company’s Chief Executive Officer, will participate in a fireside chat at Oppenheimer’s 33rd Annual Healthcare Conference being held virtually on March 13-15, 2023.

Orchard Therapeutics announced that it has entered into a securities purchase agreement for the sale of ordinary shares and warrants in a private placement that could bring in up to $188 million at increasing valuations following the achievement of U.S. regulatory milestones for OTL-200 for metachromatic leukodystrophy.

Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced business updates along with its financial results for the quarter and year ended December 31, 2022.

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for the fourth quarter and year ended December 31, 2022 (fiscal 2022) and provided a corporate update.